Levofloxacin failure in a patient with pneumococcal pneumonia

Annals of Pharmacotherapy

Volumn 35, Issue 6, 2001, Pages 687-690

  Empey, Philip E ^a,b   Jennings, Heath R ^a,b   Thornton, Alice C ^c   Rapp, Robert P ^d   Evans, Martin E ^c  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d University of Kentucky   (United States)

Author keywords

Levofloxacin; Penicillin; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G;

ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; CASE REPORT; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; LOBAR PNEUMONIA; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 0034995586     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10229     Document Type: Article

References (25)

1. The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project
2. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
3. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
4. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
5. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones
6. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents
7. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
8. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta
9. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: Correlation with penicillin resistance
10. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae
11. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance
12. Practice guidelines for the management of community-acquired pneumonia in adults
13. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
14. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
15. parC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
16. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae
17. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-Year longitudinal analysis
18. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY Antimicrobial Surveillance Program
19. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
20. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
21. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case control study
22. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae
23. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)
24. Application of fluoroquinolone pharmacodynamics